Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) saw a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 9,700 shares, a decline of 34.5% from the July 31st total of 14,800 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 23,800 shares, the short-interest ratio is presently 0.4 days.
Analysts Set New Price Targets
A number of equities analysts have weighed in on BRNS shares. Barclays lowered their price objective on Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating on the stock in a research note on Thursday, June 13th. William Blair reaffirmed an “outperform” rating on shares of Barinthus Biotherapeutics in a research note on Thursday, June 13th. Alliance Global Partners decreased their price target on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Barinthus Biotherapeutics in a research note on Monday, August 12th.
Check Out Our Latest Analysis on BRNS
Barinthus Biotherapeutics Stock Performance
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.01). On average, sell-side analysts expect that Barinthus Biotherapeutics will post -1.91 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Barinthus Biotherapeutics
Several hedge funds have recently bought and sold shares of BRNS. DC Funds LP acquired a new position in Barinthus Biotherapeutics during the 1st quarter worth about $1,528,000. BlueCrest Capital Management Ltd acquired a new position in Barinthus Biotherapeutics during the 1st quarter worth about $1,292,000. M&G Plc acquired a new position in Barinthus Biotherapeutics during the 2nd quarter worth about $7,276,000. Ipswich Investment Management Co. Inc. acquired a new position in Barinthus Biotherapeutics during the 2nd quarter worth about $32,000. Finally, Catalina Capital Group LLC acquired a new position in Barinthus Biotherapeutics during the 2nd quarter worth about $25,000. Institutional investors and hedge funds own 25.20% of the company’s stock.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Featured Stories
- Five stocks we like better than Barinthus Biotherapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- How to Find Undervalued Stocks
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Quiet Period Expirations Explained
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.